如何解读慢性乙型肝炎感染管理中的病毒标志物
Mar Riveiro-Barciela 1 , Juan M Pericàs 2 , Maria Buti 3
隶属关系
隶属关系
1
肝脏科，内科，Vall d'Hebron 大学医院，Vall d'Hebron 巴塞罗那医院校园，西班牙巴塞罗那； Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)，Instituto de Salud Carlos III，西班牙马德里；巴塞罗那自治大学（UAB），医学系。
2
肝脏科，内科，Vall d'Hebron 大学医院，Vall d'Hebron 巴塞罗那医院校园，西班牙巴塞罗那； Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)，Instituto de Salud Carlos III，西班牙马德里。
3
肝脏科，内科，Vall d'Hebron 大学医院，Vall d'Hebron 巴塞罗那医院校园，西班牙巴塞罗那； Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)，Instituto de Salud Carlos III，西班牙马德里；巴塞罗那自治大学（UAB），医学系。电子地址：[email protected]。
How to interpret viral markers in the management of chronic hepatitis B infection
Mar Riveiro-Barciela 1 , Juan M Pericàs 2 , Maria Buti 3
Affiliations
Affiliations
1
Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Universitat Autònoma de Barcelona (UAB), Department of Medicine.
2
Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
3
Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Universitat Autònoma de Barcelona (UAB), Department of Medicine. Electronic address: [email protected].
PMID: 34768018 DOI: 10.1016/j.cmi.2021.10.020
Abstract
Background: Hepatitis B virus (HBV) infection is a global public health issue with several unsolved clinical challenges. As multiple new drugs are under development, HBV markers are gaining importance for both diagnostic and prognostic purposes.
Objectives: This review summarizes the most important data on the usefulness of HBV markers in the natural history of this infection, and in predicting clinical and treatment outcomes.
Sources: Selected peer-reviewed publications on HBV markers published between January 2009 and July 2021.
Content: In addition to the classical markers (eg, HBV-DNA), newer ones, such as quantitative HBsAg, HBcrAg, HBV-RNA and quantitative anti-HBc, have proven useful for predicting events within the natural history of HBV infection, the development of complications (eg, hepatocellular carcinoma), and the response to antiviral therapy. Most data regarding the response to treatment have been related to nucleos(t)ide analogues, whereas evidence on new therapeutic agents, such as capsid assembly modulators or small interference RNAs, is promising, but still scarce.
Implications: Knowledge on the use of viral markers is a key factor for optimizing the clinical appraisal of HBV infection. The new markers have an enhanced ability to predict clinical outcomes. Further studies should expand the current evidence on the use of markers in relation to antiviral agents currently under evaluation. Wide availability of these markers in regions with a high incidence of HBV infection is of paramount importance.